Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma
Crossref DOI link: https://doi.org/10.1007/s00384-017-2800-1
Published Online: 2017-04-19
Published Print: 2017-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Rivera, Fernando
Karthaus, Meinolf
Hecht, J. Randolph
Sevilla, Isabel
Forget, Frédéric
Fasola, Gianpiero
Canon, Jean-Luc
Guan, Xuesong
Demonty, Gaston
Schwartzberg, Lee S.
Funding for this research was provided by:
Amgen
License valid from 2017-04-19